A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis

Inclusion Criteria:

• Taken part in either of the prior PRM-151 studies: PRM-151-202 or WA42293.

• For women of childbearing potential: agreement to remain abstinent (refrain fromheterosexual intercourse) or use contraception.

• For men: agreement to remain abstinent (refrain from heterosexual intercourse) oruse a condom, and agreement to refrain from donating sperm.

Exclusion Criteria:

• Acute respiratory or systemic bacterial, viral, or fungal infection at the firstvisit of the OLE, or within 2 weeks of the first visit for patients joining Cohort A (from Study PRM-151-202).

• History of smoking within 3 months prior to the first visit in the OLE.

• History of alcohol or substance use disorder within 2 years prior to the first visitof the OLE or known or suspected active alcohol or substance-use disorder.

• History of severe allergic reaction or anaphylactic reaction to PRM-151.

• Clinically significant abnormality on ECG during eligibility assessment that, in theopinion of the investigator, may pose an additional risk in administering study drugto the participant.

• Prolonged corrected QT interval > 450 ms (for men) or > 470 ms (for women) based onthe Fridericia correction formula.

• Clinically significant laboratory test abnormalities (hematology, serumchemistry,and urinalysis) that, in the opinion of the investigator, may pose an additionalrisk in administering study drug to the participant.